LVTX

LAVA Therapeutics NV

LVTX, USA

LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.

https://www.lavatherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LVTX
stock
LVTX

LAVA Therapeutics (LVTX) Expected to Announce Earnings on Tuesday Defense World

Read more →
LVTX
stock
LVTX

LAVA Therapeutics Delists from Nasdaq and Changes Leadership TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$1.5054

Analyst Picks

Strong Buy

1

Buy

0

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.69

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-56.67 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-13.85 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

3.09

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 32.43% of the total shares of LAVA Therapeutics NV

1.

Redmile Group, LLC

(7.8858%)

since

2025/06/30

2.

BML Capital Management LLC

(7.4913%)

since

2025/06/30

3.

Sanofi

(7.2968%)

since

2025/06/30

4.

Merck & Co Inc

(4.3693%)

since

2025/06/30

5.

Bruce & Co Inc

(1.9839%)

since

2025/06/30

6.

Bruce

(1.9839%)

since

2025/06/30

7.

Pathway Financial Advisors LLC

(0.3897%)

since

2025/06/30

8.

PNC Financial Services Group Inc

(0.2471%)

since

2025/06/30

9.

Citadel Advisors Llc

(0.1969%)

since

2025/06/30

10.

BNP Paribas Arbitrage, SA

(0.1783%)

since

2025/06/30

11.

Two Sigma Investments LLC

(0.1308%)

since

2025/06/30

12.

UBS Group AG

(0.0623%)

since

2025/06/30

13.

TWO SIGMA SECURITIES, LLC

(0.0541%)

since

2025/06/30

14.

Geode Capital Management, LLC

(0.0539%)

since

2025/06/30

15.

Fidelity Nasdaq Composite Index

(0.0539%)

since

2025/07/31

16.

Morgan Stanley - Brokerage Accounts

(0.0441%)

since

2025/06/30

17.

TSFG, LLC

(0.0015%)

since

2025/03/31

18.

JONES FINANCIAL COMPANIES LLLP

(0.0015%)

since

2025/06/30

19.

SBI Securities Co Ltd

(0.0011%)

since

2025/06/30

20.

Millennium Management LLC

(0%)

since

2025/03/31

21.

Atlantic Trust Group, LLC

(0%)

since

2025/03/31

22.

Virtu Financial LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.24

Latest Release

Date

2025-09-30

EPS Actual

-0.27

EPS Estimate

-0.245

EPS Difference

-0.025

Surprise Percent

-10.2041%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Possible Net-Net(4)
Quality
Low Quality Business(1)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.